Abstract
This work studied the mechanisms of interaction between Eudragit RS100 (RS) and RL100 (RL) polymers with 3 nonsteroidal anti-inflammatory drugs: diflunisal (DIF), flurbiprofen (FLU), and piroxicam (PIR). Solid dispersions of polymers and drugs at different weight ratios were prepared by coevaporation of their ethanol solutions. The resulting coevaporates were characterized in the solid state (Fourier-transformed infrared spectroscopy (FT-IR) IR, differential scanning calorimetry, powder-x-ray diffractometry) as well as by studying the in vitro drug release in a gastroenteric environment. Absorption tests from drug solutions to the solid polymers were also performed to better explain the mechanism of interactions between them. The preparative conditions did not induce changes in the crystalline state of the drugs (amorphization or polymorphic change). Drugs strongly interacted with the ammonium groups present in polymers, giving an electrostatic interaction that reinforced the mere physical dispersion of drug molecules within polymer networks. Such interactions are related to the chemical structure of the drugs and to their dissociated or undissociated state. The dispersion of drugs in the polymer matrices strongly influenced their dissolution rate, which appeared slower and more gradual than those of the pure drugs, when polymer ratios were increased. RL coevaporates usually displayed higher dissolution rates. The kinetic evaluation of the dissolution profile, however, suggested that both the drug solubility in the external medium and its diffusion capacity within the polymer network are involved. In the sorption experiments, RL showed a greater adsorptive capacity than RS, in relation to the greater number of quaternary ammonium functions, which behave as activity sites for the electrostatic interactions. In the presence of Tris-HCl buffer (pH 7.4), drug adsorption was reduced, as a consequence of the competition of the chloride ions with drug anions for the polymer binding sites. In general, DIF and FLU displayed a similar interaction with RS and RL active sites; PIR's was different. The different molecular structures of these agents can justify such findings. The presence of a carboxyl group (instead of another dissociable acidic moiety, like the hydroxy-enolic one in the PIR molecule) could help explain the strong interaction with RS and RL polymers' quaternary ammonium centers. Preliminary studies like ours are important in helping develop better forecasting and increasing the understanding of the incorporation/release behavior of drugs from particulate delivery systems that can be made from these polymers.
Key Words: Eudragit RS100, Eudragit RL100, diflunisal, flurbiprofen, piroxicam, solid dispersions, coevaporates
Full Text
The Full Text of this article is available as a PDF (740.2 KB).
References
- 1.Goto S, Kawata M, Nakamura M, Maekauwa K, Ayoama T. Eudragit RS and RL (acrylic resins) micro-capsules as pH insensitive and sustained release preparations of ketoprofens. J Microencapsul. 1986;3:293–304. doi: 10.3109/02652048609021799. [DOI] [PubMed] [Google Scholar]
- 2.Kawata M, Nakamura M, Goto T, Ayoama T. Preparation and dissolution pattern of Eudragit RS microcapsules containing ketoprofen. Chem Pharm Bull. 1986;34:2618–2623. doi: 10.1248/cpb.34.2618. [DOI] [PubMed] [Google Scholar]
- 3.Kawashima Y, Iwamoto T, Niwa T, Takeuchi H, Hino T. Size control of ibuprofen microspheres with an acrylic polymer by changing the pH in an aqueous dispersion medium and its mechanisms. Chem Pharm Bull. 1993;41:191–195. [Google Scholar]
- 4.Murthy T, Verma P. Controlled transdermal delivery of flurbiprofen films using mixed grades of Eudragit: design, in-vitro and in-vivo evaluation. Int J Pharm Adv. 1996;1:391–397. [Google Scholar]
- 5.Pignatello R, Spedalieri G, Bucolo C, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;15:3247–55. doi: 10.1016/S0142-9612(02)00080-7. [DOI] [PubMed] [Google Scholar]
- 6.Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002;16:53–61. doi: 10.1016/S0928-0987(02)00057-X. [DOI] [PubMed] [Google Scholar]
- 7.Benita S, Hoffman A, Donbrow M. Microencapsulation of paracetamol using polyacrylate resins (Eudragit Retard): kinetics of drug release and evaluation of kinetic model. J Pharm Pharmacol. 1985;37:391–395. doi: 10.1111/j.2042-7158.1985.tb03021.x. [DOI] [PubMed] [Google Scholar]
- 8.Beten DB, Moës AJ. Controlled-release coevaporates of dipyridamole prepared with acrylic polymers. Int J Pharm. 1994;103:243–251. doi: 10.1016/0378-5173(94)90174-0. [DOI] [Google Scholar]
- 9.Jenquin MR, McGinity JW. Characterization of acrylic resin matrix films and mechanisms of drug-polymer interactions. Int J Pharm. 1994;10:23–34. doi: 10.1016/0378-5173(94)90072-8. [DOI] [Google Scholar]
- 10.Lin SY, Cheng CL, Perng RI. Solid state interaction studies of drug-polymers: II. Warfarin-Eudragit E, RL or S resins. Eur J Pharm Sci. 1994;1:313–322. doi: 10.1016/0928-0987(94)90040-X. [DOI] [Google Scholar]
- 11.Jenquin MR, Liebowitz SM, Sarabia RE, McGinity JW. Physical and chemical factors influencing the release of drugs from acrylic resin films. J Pharm Sci. 1990;79:811–816. doi: 10.1002/jps.2600790914. [DOI] [PubMed] [Google Scholar]
- 12.Oth MP, Moës AJ. Sustained release solid dispersions of indomethacin with Eudragit RS and RL. Int J Pharm. 1989;55:157–164. doi: 10.1016/0378-5173(89)90037-9. [DOI] [Google Scholar]
- 13.Kislalioglu MS, Khan MA, Blount C, Goettsh RW, Bolton S. Physical characterisation and dissolution properties of ibuprofen-Eudragit coprecipitates. J Pharm Sci. 1991;80:799–804. doi: 10.1002/jps.2600800820. [DOI] [PubMed] [Google Scholar]
- 14.Pignatello R, Vandelli MA, Giunchedi P, Puglisi G. Properties of tolmetin-loaded Eudragit RL100 and RS100 microparticles prepared by different techniques. S.T.P. Pharma Sciences. 1997;7:148–157. [Google Scholar]
- 15.Heun G, Lambov N, Groning R. Experimental and molecular modelling studies on interactions between drugs and Eudragit RL/RS resins in aqueous environment. Pharm Acta Helv. 1998;73:57–62. doi: 10.1016/S0031-6865(97)00053-8. [DOI] [Google Scholar]
- 16.Pignatello R, Ferro M, De Guidi G, et al. Preparation, characterisation and photosensitivity studies of solid dispersions of diflunisal and Eudragit RS100® and RL100®. Int J Pharm. 2001;218:27–42. doi: 10.1016/S0378-5173(01)00597-X. [DOI] [PubMed] [Google Scholar]
- 17.Pignatello R, Consoli P, Puglisi G. In vitro release kinetics of Tolmetin from tabletted Eudragit microparticles. J Microencapsul. 2000;17:373–383. doi: 10.1080/026520400288337. [DOI] [PubMed] [Google Scholar]
- 18.Vrecer F, Srcic S, Šmid-Korbar J. Investigation of piroxicam polymorphism. Int J Pharm. 1991;68:35–41. doi: 10.1016/0378-5173(91)90124-7. [DOI] [Google Scholar]